Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2021 07:00 ET | Source: AC Immune SA

AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference

LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
February 11, 2021 07:00 ET | Source: AC Immune SA

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease ACI-35.030 was...
February 08, 2021 07:00 ET | Source: AC Immune SA

AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
January 29, 2021 07:00 ET | Source: AC Immune SA

AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway

Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors High-affinity antibodies against extracellular components of the inflammasome pathway show...
December 15, 2020 08:00 ET | Source: AC Immune SA

AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital Proprietary SupraAntigenTM platform continues to accelerate...
November 20, 2020 08:40 ET | Source: AC Immune SA

Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directors

Prof. June is a world authority on immune tolerance and adoptive immunotherapy Appointment reaffirms AC Immune’s scientific leadership in neurodegeneration LAUSANNE, Switzerland, Nov. 20, 2020 ...
November 18, 2020 07:00 ET | Source: AC Immune SA

Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer

Prof. Streffer is an established authority on neuroscience and biomarker modalities Appointment reaffirms AC Immune’s scientific leadership in neurodegeneration LAUSANNE, Switzerland, Nov. 18,...
November 13, 2020 07:00 ET | Source: AC Immune SA

AC Immune Reports Q3 2020 Financial Results and Provides Business Update

Phase 1 trial completed in Lilly Morphomer™ Tau partnership program with plans to evaluate candidates in Alzheimer’s disease and NeuroOrphan indicationsFirst-in-class TDP-43 therapeutic and diagnostic...
November 12, 2020 07:00 ET | Source: AC Immune SA

AC Immune to Provide Strategy and Pipeline Update During Jefferies Virtual London Healthcare Conference

LAUSANNE, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
November 09, 2020 04:00 ET | Source: AC Immune SA

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

LAUSANNE, Switzerland, Nov. 09, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...